We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Nanofluidic Device Traps and Concentrates Pathogenic Bacteria

By LabMedica International staff writers
Posted on 31 Mar 2020
A nanofluidic device containing stacked magnetic beads of different sizes has been developed to efficiently trap, concentrate, and retrieve Escherichia coli (E. coli) bacteria from liquid suspensions.

The miniaturized, inexpensive, and transparent device developed by investigators at Rutgers University (Rochester, NY, USA) and the Rochester Institute of Technology (NY, USA) is easy to fabricate and operate, making it ideal for pathogen separation in both laboratory and point-of-care settings.

The investigators used computational fluid dynamics, three-dimensional tomography technology, and machine learning to probe and explain the effects of bead stacking in a small three-dimensional space with various flow rates. Ultimately, a combination of beads with different sizes was utilized to achieve a high capture efficiency (approximately 86%) with a flow rate of 50 microliters per minute.

In addition, the investigators showed that the high deformability of the device enabled retrieval of an E. coli sample from a bacterial suspension by applying a higher flow rate followed by rapid magnetic separation. This unique function was also utilized to concentrate E. coli cells from the original bacterial suspension. An on-chip concentration factor of about 11 times was achieved by inputting 1300 microliters of the E. coli sample and then concentrating it down to 100 microliters.

The new device is expected to play an important role in the identification and isolation of drug resistant strains of bacteria, from which at least 700,000 people die each year, including 230,000 deaths from multidrug-resistant tuberculosis.

"The rapid identification of drug-resistant bacteria allows health care providers to prescribe the right drugs, boosting the chances of survival," said contributing author Dr. Ruo-Qian (Roger) Wang, assistant professor of civil and environmental engineering at Rutgers University.

The nanofluidic device was described in the February 19, 2020, issue of the journal ACS Applied Materials & Interfaces.

Related Links:
Rutgers University
Rochester Institute of Technology



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.